The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Treatment of Obstructive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy With β-Blockade or Verapamil
Open accessAbstract
BACKGROUND: There is controversy about preferred methods to relieve obstruction in hypertrophic cardiomyopathy patients still symptomatic after β-blockade or verapamil. METHODS AND RESULTS: Of 737 patients prospectively registered at our institution, 299 (41%) required further therapy for obstruction for limiting symptoms, rest gradient 61 ± 45, provoked gradient 115 ± 49 mm Hg, and followed up for 4.8 years. Disopyramide was added in 221 (74%) patients and pharmacological control of symptoms was achieved in 141 (64%) patients. Overall, 138 (46%) patients had surgical relief of obstruction (91% myectomy) and 6 (2%) alcohol septal ablation. At follow-up, resting gradients in the 299 patients had decreased from 61 ± 44 to 10 ± 25 mm Hg (P<0.0001); New York Heart Association class decreased from 2.7 ± 0.7 to 1.8 ± 0.5 (P<0.0001). Kaplan-Meier survival at 10 years in the 299 advanced-care patients was 88% and did not differ from nonobstructed patients (P=0.28). Only 1 patient had sudden death, a low annual rate of 0.06%/y. Kaplan-Meier survival at 10 years in the advanced-care patients did not differ from that expected in a matched cohort of the US population (P=0.90). CONCLUSIONS: Patients with obstruction and symptoms resistant to initial pharmacological therapy with β-blockade or verapamil may realize meaningful symptom relief and low mortality through stepped management, adding disopyramide in appropriately selected patients, and when needed, by surgical myectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Disopyramide has been shown in retrospective studies to be safe and associated with an improvement in both LVOT gradient and symptoms when used in combination with β blockers or non-dihydropyridine CCBs.”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [31]
In the citing paper
“has been shown to reduce LV outflow gradient and improve symptoms in patients with hypertrophic cardiomyopathy.[662][663][664]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [664]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,116
Hypertensive, Y., & Chin, K. (1982) · Springer eBooks · doi:10.1007/978-3-642-68282-7 · Cited by 1,757
Maron, B. J., McKenna, W. J., Danielson, G. K., KAPPENBERGER, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H., Spirito, P., ten Cate, F. J., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00941-0 · Cited by 1,572
Maron, M. S., Olivotto, I., Betocchi, S., Casey, S. A., Lesser, J. R., Losi, M. A., Cecchi, F., & Maron, B. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021332 · Cited by 1,259
Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction
Maron, M. S., Olivotto, I., Zenovich, A. G., Link, M. S., Pandian, N. G., Kuvin, J. T., Nistri, S., Cecchi, F., Udelson, J. E., & Maron, B. J. (2006) · Circulation · doi:10.1161/circulationaha.106.644682 · Cited by 1,127
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e230 · Cited by 825
Ommen, S. R., Maron, B. J., Olivotto, I., Maron, M. S., Cecchi, F., Betocchi, S., Gersh, B. J., Ackerman, M. J., McCully, R. B., Dearani, J. A., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.090 · Cited by 812
Wigle, E. D., Rakowski, H., Kimball, B. P., & Williams, W. G. (1995) · Circulation · doi:10.1161/01.cir.92.7.1680 · Cited by 775
Maron, B. J., Nishimura, R. A., McKenna, W. J., Rakowski, H., Josephson, M. E., & Kieval, R. S. (1999) · Circulation · doi:10.1161/01.cir.99.22.2927 · Cited by 490
Sherrid, M. V., Barac, I., McKenna, W. J., Elliott, P. M., Dickie, S., Chojnowska, L., Casey, S., & Maron, B. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.012 · Cited by 410 · cited 2×
“Nevertheless, we continue the surveillance described above in our disopyramide-treated patients.(3,7) We”
Method
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–178 of 178
Surgical Septal Myectomy and Alcohol Ablation
Sherrid, M. V., Massera, D., & Swistel, D. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.332 · Cited by 7
An overview of the treatments for hypertrophic cardiomyopathy
Xu, W., Zhu, F., Zhang, Y., Li, P., & Sheng, Y. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1387596 · Cited by 6
Thin-Filament Mutations, Hypertrophic Cardiomyopathy, and Risk ∗
Sherrid, M. V., Arabadjian, M. E., & Koulova, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.10.007 · Cited by 6
Tajima, M., Iguchi, N., Utanohara, Y., Hiroi, Y., Mahara, K., Niwa, T., Takayama, M., Sumiyoshi, T., & Tomoike, H. (2016) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2016.07.015 · Cited by 6
Hypertrophic Cardiomyopathy: The Past, the Present, and the Future
D, E. B. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_1 · Cited by 6
Kubo, T., Sugiura, K., Tokita, Y., Takano, H., Takamisawa, I., Takayama, M., Doi, Y., Minami, Y., Shirotani, S., Ebato, M., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-324811 · Cited by 5
MOCHIZUKI, Y., Suzuki, R. H., Yasumura, Y., Saito, T., Teshima, T., Matsumoto, H., & Koyama, H. (2019) · Journal of Veterinary Medical Science · doi:10.1292/jvms.18-0718 · Cited by 5
An, S., Fan, C., Yang, Y., Hang, F., Wang, Z., Zhang, Y., & Zhang, J. (2018) · Cardiology · doi:10.1159/000484628 · Cited by 5
Indications for Surgery in Obstructive Hypertrophic Cardiomyopathy
Sherrid, M. V. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.019419 · Cited by 5
Calore, C., Mangia, M., Basso, C., Corrado, D., & Thiene, G. (2025) · Genes · doi:10.3390/genes16010074 · Cited by 5
A Practical Approach to Multimodality Imaging in Hypertrophic Cardiomyopathy
Dalsania, A. K., Park, C. M., Nagraj, S., Lorenzatti, D., Filtz, A., Weissler‐Snir, A., Garcia, M. J., Slipczuk, L. N., & Schenone, A. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082606 · Cited by 4
Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy
Hidalgo, L. F., Naidu, S. S., & Aronow, W. S. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1417038 · Cited by 4
Maron, B. J., Maron, M. S., Sherrid, M. V., Ommen, S. R., & Rowin, E. J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.033 · Cited by 4
Hypertrophic Obstructive Cardiomyopathy with SAM Phenomenon: A Case Report and Literature Review
Cai, M.-L., & Zhong, G. (2022) · Cardiology and Cardiovascular Medicine · doi:10.26502/fccm.92920293 · Cited by 4
A complex unit for a complex disease: the HCM-Family Unit
Vriz, O., Alsergani, H., Elshaer, A. N., Shaik, A., Mushtaq, A. H., Lioncino, M., Alamro, B., Monda, E., Caiazza, M., Mauro, C., et al. (2021) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2021.2147 · Cited by 5
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Masri, A., Maron, M. S., Abraham, T. P., Nassif, M. E., Villa, R. B., Bilen, O., COATS, C. J., Elliott, P., García‐Pavía, P., Massera, D., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.008 · Cited by 3
Sun, S., Wei, Y., Wang, H., Tang, L., & Deng, B. (2020) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmaa098 · Cited by 3
Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.02.009 · Cited by 3
Harano, Y., Kawase, Y., & Matsuo, H. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytac311 · Cited by 3
Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy
O’Mahony, C., MOHIDDIN, S. A., & Knight, C. J. (2011) · Interventional Cardiology Reviews Research Resources · doi:10.15420/articles/alcohol-septal-ablation-treatment-hypertrophic-obstructive-cardiomyopathy · Cited by 3
Oh, J. S., Seo, J.-Y., Lee, C.-M., Jung, S.-J., Kim, J., & Chon, M. K. (2024) · Biomedicines · doi:10.3390/biomedicines12122762 · Cited by 2
Grupper, A., Sverdlov, A. L., Cheema, B. S., Nasrollahizadeh, A., & Hosseini, K. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10603-9 · Cited by 2
Alharbi, T. Y., Alnadawi, H. A., Almutairi, G. M., Altheyab, F. Y., Aldoweesh, O. H., Alfehaid, O. S., Alhaj, A. A., Alotaibi, A. M., & Zweihary, A. M. A. (2024) · Cureus · doi:10.7759/cureus.70550 · Cited by 2
Saddique, M. N., Irfan, H., Ashraf, S., Qadri, M., Javaid, H., Iftikhar, S., Haq, M. Z. U., Fatima, L., Mehmood, Q., Jha, A., et al. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100535 · Cited by 2
Cardim, N. M., Pellerin, D., & Valente, F. X. (2016) · doi:10.1093/med/9780198726012.003.0042 · Cited by 2
Modern Perspectives on Hypertrophic Cardiomyopathy—No One Size Fits All
Doliner, B., Gaddar, H., Kalil, R. K., & Postalian, A. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-24-8423 · Cited by 2
Indications for and Individualization of Septal Reduction Therapy
Feldman, D. N., Douglas, J. S., & Naidu, S. S. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4956-9_17 · Cited by 2
Almanac 2014: Cardiomyopathies.
Guttmann, O. P., MOHIDDIN, S. A., & Elliot, P. M. (2015) · Cardiologia Croatica · doi:10.15836/ccar.2014.543 · Cited by 2
Hypertrophic Cardiomyopathy and Pregnancy
van Hagen, I. M., Elkayam, U., Goland, S., & Roos‐Hesselink, J. W. (2019) · Wiley eBooks · doi:10.1002/9781119409861.ch12 · Cited by 3
New Frontiers in Hypertrophic Obstructive Cardiomyopathy
Parniani, A., Carroll, D., & Cios, T. J. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.09.005 · Cited by 2
Othman, L., Koskina, L. E., Huerta, N. H., & Rao, S. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10476-w · Cited by 1
Hurst, M. A., Zema, C., Krause, T., Sandler, B. C., Lemmer, T., Noon, K. M., Alexander, D., & Osman, F. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080142 · Cited by 1
Pugsley, M. K., Hwee, D. T., Winters, B. R., Wang, J., Chin, E. R., Morgan, B. P., & Malik, F. I. (2025) · International Journal of Toxicology · doi:10.1177/10915818251326466 · Cited by 1
Cardiac Hypertrophy: A Comprehensive Review from Prenatal Life to Young Adulthood
Avesani, M., Pomiato, E., Moscatelli, S., Sabatino, J., Borrelli, N., Luedke, L., Sarro, R. D., Pavesi, S., Pelaia, G., Mastellone, C., et al. (2025) · Children · doi:10.3390/children12080989 · Cited by 1
Multidisciplinary management of patients with hypertrophic cardiomyopathy
Rudenko, K. V., Danchenko, P. A., Rzhanyi, M., Chyzhevska, O. O., Bei, A. O., & Kovalyova, O. M. (2026) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2026.1.7585 · Cited by 1
Weiner, S. D., Liang, L. W., Masri, A., Abraham, T. P., Villa, R. B., Cooper, R. M., Elliot, P. M., de Feria, A., Maron, M. S., Oręziak, A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag244 · Cited by 1
Gardner, M., Nair, V., Hu, D. J., & Derry, S. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.09.003 · Cited by 1
Ma, Y., Liu, L., Yuan, L., & Lee, A. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-6957-9_10 · Cited by 1
Todde, G., Dei, L., Polizzi, R., Gabrielli, D., Canciello, G., Romano, S., Borrelli, F., Hálasz, G., Ordine, L., Napoli, S., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1416600 · Cited by 1
Isobe, S., Ieda, M., Kohno, T., Nishiyama, T., Maekawa, Y., Tsuruta, H., Murata, M., Yashima, F., Yanagisawa, R., Tanaka, M., et al. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002629 · Cited by 1
Hypertrophic Cardiomyopathy (HCM)
Song, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-50141-3_9 · Cited by 1
Spindel, J., Mathbout, M. F., & Ghafghazi, S. (2021) · Echocardiography · doi:10.1111/echo.14969 · Cited by 1
Indications for and Individualization of Septal Reduction Therapy
Feldman, D. N., Douglas, J. S., & Naidu, S. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_22 · Cited by 1
Guo, L., Su, Y., Chen, C., Zhou, Q. A., Shen, Y., Jiang, Z., Xia, Y., Li, X., Zhuo, W., Peng, X., et al. (2022) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.29 · Cited by 1
Disopyramide for symptomatic obstructive hypertrophic cardiomyopathy
Sherrid, M. V., & Massera, D. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133030 · Cited by 1
Pediatric Diagnosis and Management
Colan, S. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4956-9_9
Out With the Old and in With the New
Maron, M. S. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.002
Assistant Professor of CTVS, V. &. S., & Padhy, D. A. K. (2020) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v8i3.46
Almanac 2014: cardiomyopathies
Guttmann, O. P., MOHIDDIN, S. A., & Elliot, P. M. (2015) · Cor et Vasa · doi:10.1016/j.crvasa.2015.01.002
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Diagnosis, Clinical Course and Therapy
Lazzeroni, D., & Centorbi, C. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97033
Miocardiopatías. Miocardiopatía hipertrófica
Campos, A. G., Domínguez, M. P., & González-Juanatey, B. D. F. Y. J. R. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.09.020
Medical Therapy: From Beta-Blockers to Disopyramide
Mankowitz, K., & Sherrid, M. V. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_15
Pediatric Diagnosis and Management
Colan, S. D., & Miliaresis, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_9
Assim, S. B., Al-Kinani, T., & AL-Obaidi, F. R. (2021) · Intervenční a akutní kardiologie · doi:10.36290/kar.2021.033
Cardim, N. M., Toste, A., & Nijveldt, R. (2021) · doi:10.1093/med/9780198849353.003.0043
(2016) · Elsevier eBooks · doi:10.1016/b978-0-323-26011-4.09966-6
Research Progress in the Diagnosis and Treatment of HCM
唐, 雍. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1392054
Use of Disopyramide in Obstructive Hypertrophic Cardiomyopathy: A European Insight
Charron, P., Osman, F., Trochu, J., Zema, C., Hurst, M. A., Sandler, B. C., Cotté, F.-E., Lemmer, T., & Tome, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114234
Spezielle medikamentöse und interventionelle Therapieverfahren der hypertrophen Kardiomyopathie
Seggewiß, H., & Batzner, A. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2285-3854
Vecchio, K. D., Rizzardi, C., Pozza, A., Prati, F., Ye, L., Fattoretto, A., Reffo, E., & Salvo, G. D. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.3084
Inhibidores de la miosina en miocardiopatía hipertrófica obstructiva
Alén, A., Reguero, J. J. R., & Lorca, R. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106971
Myosin inhibitors in obstructive hypertrophic cardiomyopathy
Alén, A., Reguero, J. J. R., & Lorca, R. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106971
Pediatric Diagnosis and Management
Miliaresis, C., Warsy, I. A., & Colan, S. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_13
Indications for and Individualization of Septal Reduction Therapy
Naidu, S. S., Douglas, J. S., & Ommen, S. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_23
Pharmacologic Therapy of Hypertrophic Cardiomyopathy 1964–2024: From Beta-Blockers to Disopyramide
Sherrid, M. V., & Massera, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_18
Approach to the Initial and Follow-Up Visits
Spirito, P., & Autore, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_29
Therapeutic Sequencing in Obstructive Hypertrophic Cardiomyopathy
Reza, N. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102836
Aficamten Monotherapy for Hypertrophic Cardiomyopathy
Ahamed, H., Ommen, S. R., & Rowin, E. J. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2514558
Medical Therapy: From Beta–Blockers to Disopyramide
Mankowitz, K. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4956-9_14
Heart Failure and Genetic Cardiomyopathies
Ionescu, B. I., García‐Pavía, P., & Jurcut, R. O. (2025) · Springer eBooks · doi:10.1007/978-3-031-96562-3_22
Surgical management of hypertrophic cardiomyopathy
Ananthanarayanan, C., Modugula, S., Chauvette, V., Ragheb, D. K., Bhagat, R., & Smedira, N. (2026) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-026-02180-1
Hazique, M., SURANA, A., Singh, B., Burhan, M., Alraies, M. C., & Bhinder, J. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001818
Wilborn, T. W., Fasinu, P. S., & Coric, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00590-x
Medical Management of Hypertrophic Cardiomyopathy
Gupta, M. D., Goel, V., & Girish, M. P. (2026) · Indian Heart Journal · doi:10.1016/j.ihj.2026.06.005
Schulz, A., Maron, M. S., Peng, L. W., Maron, B. A., Amyar, A., Ngo, L. H., Olivotto, I., Chan, R. H. M., Manning, W. J., Rowin, E. J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048066
Mureşan, L., Cismaru, G., Popa, S., Roşu, R., Guşetu, G., Puiu, M., Mada, R. O., Muresan, C., Bouar, R. L., Schiau, S., et al. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00828-2
Merlo, M., Sinagra, G., Finocchiaro, G., Folgheraiter, A., Rizzi, J. G., Sperandeo, F., & Virili, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-34334-5_5
Cardiac Hypertrophy and Hypertrophic Cardiomyopathy: Introduction and Management
Beigel, R., Siegel, R. J., & Rader, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_16
Metadata
- Authors
- Sherrid, M. V., Shetty, A., Winson, G., Kim, B., Musat, D., Alviar, C. L., Homel, P., Balaram, S. K., & Swistel, D. G.
- Affiliations
- St. Luke's-Roosevelt Hospital Center (US)
- ORCID
- Venue
- Circulation Heart Failure
- Published
- 2013-07
- Volume
- 6
- Issue
- 4
- Pages
- 694-702
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2122819292
- Cited by
- 178
- References
- 33
- Citations by year
- 2026: 11 · 2025: 26 · 2024: 26 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 11 · 2019: 6 · 2018: 13 · 2017: 7 · 2016: 14 · 2015: 10 · 2014: 13 · 2013: 1
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Heart Failure (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Keywords
- hypertrophic obstructive cardiomyopathy, left ventricular outflow tract obstruction, disopyramide, beta-adrenergic blockade, verapamil, myectomy, alcohol septal ablation, symptom relief, survival, sudden death
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Anti-Arrhythmia Agents, Calcium Channel Blockers, Cardiomyopathy, Hypertrophic, Combined Modality Therapy, Disopyramide, Female, Cardiac Surgical Procedures, Humans, Male, Middle Aged, Verapamil, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
